📊 LIVN Key Takeaways
Is LIVN a Good Investment? Thesis Analysis
LivaNova demonstrates solid revenue growth (10.7% YoY) and maintains a healthy 67.7% gross margin with strong operating cash flow generation ($254.3M), but is severely unprofitable with -$242.5M net loss that worsened -483.5% YoY. The significant divergence between positive operating cash flow and negative net income, combined with negative ROE (-20.2%) and ROA (-9.3%), signals serious operational challenges or substantial non-cash charges requiring resolution before shareholder value can be restored.
Why Buy LIVN? Key Strengths
- Strong revenue growth at 10.7% YoY with $1.4B total revenue
- Excellent gross margin of 67.7% demonstrates pricing power and cost management
- Robust operating cash flow of $254.3M with positive free cash flow of $173.3M and 12.5% FCF margin
- Conservative balance sheet with 0.31x debt-to-equity ratio, strong 12.5x interest coverage, and $635.6M cash position
LIVN Investment Risks to Consider
- Company is deeply unprofitable with -17.5% net margin and -$242.5M net loss, deteriorating sharply (-483.5% YoY)
- Negative returns on equity (-20.2%) and assets (-9.3%) indicate sustained shareholder value destruction
- Significant divergence between strong operating cash flow and large net losses suggests major non-cash charges, impairments, or operational issues requiring clarification
Key Metrics to Watch
- Return to profitability and timeline for net income recovery
- Explanation and sustainability of operating cash flow positive divergence versus negative net income
- Operating margin expansion and ability to convert revenue growth into earnings
LIVN Financial Metrics
💡 AI Analyst Insight
LivaNova PLC presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
LIVN Profitability Ratios
LIVN vs Healthcare Sector
How LivaNova PLC compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is LIVN Overvalued or Undervalued?
Based on fundamental analysis, LivaNova PLC has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
LIVN Balance Sheet & Liquidity
LIVN 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: LivaNova PLC's revenue has grown significantly by 28% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.32 reflects profitable operations.
LIVN Growth Metrics (YoY)
LIVN Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $318.1M | $7.3M | $0.13 |
| Q2 2025 | $318.6M | $16.3M | $0.30 |
| Q1 2025 | $294.9M | -$41.9M | $-0.78 |
| Q3 2024 | $286.1M | $1.2M | $0.02 |
| Q2 2024 | $293.9M | $1.2M | $0.02 |
| Q1 2024 | $263.4M | $7.4M | $0.14 |
| Q3 2023 | $252.6M | $1.2M | $0.02 |
| Q2 2023 | $254.2M | $1.2M | $0.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
LIVN Capital Allocation
LIVN SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for LivaNova PLC (CIK: 0001639691)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 1, 2026 | 4 | xslF345X06/wk-form4_1775078427.xml | View → |
| Apr 1, 2026 | 4 | xslF345X06/wk-form4_1775078421.xml | View → |
| Apr 1, 2026 | 4 | xslF345X06/wk-form4_1775078415.xml | View → |
| Apr 1, 2026 | 4 | xslF345X06/wk-form4_1775078409.xml | View → |
| Apr 1, 2026 | 4 | xslF345X06/wk-form4_1775078403.xml | View → |
❓ Frequently Asked Questions about LIVN
What is the AI rating for LIVN?
LivaNova PLC (LIVN) has an AI rating of SELL with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are LIVN's key strengths?
Claude: Strong revenue growth at 10.7% YoY with $1.4B total revenue. Excellent gross margin of 67.7% demonstrates pricing power and cost management.
What are the risks of investing in LIVN?
Claude: Company is deeply unprofitable with -17.5% net margin and -$242.5M net loss, deteriorating sharply (-483.5% YoY). Negative returns on equity (-20.2%) and assets (-9.3%) indicate sustained shareholder value destruction.
What is LIVN's revenue and growth?
LivaNova PLC reported revenue of $1.4B.
Does LIVN pay dividends?
LivaNova PLC does not currently pay dividends.
Where can I find LIVN SEC filings?
Official SEC filings for LivaNova PLC (CIK: 0001639691) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LIVN's EPS?
LivaNova PLC has a diluted EPS of $-4.45.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LIVN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, LivaNova PLC has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is LIVN stock overvalued or undervalued?
Valuation metrics for LIVN: ROE of -20.2% (sector avg: 15%), net margin of -17.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy LIVN stock in 2026?
Our dual AI analysis gives LivaNova PLC a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LIVN's free cash flow?
LivaNova PLC's operating cash flow is $254.3M, with capital expenditures of $81.1M. FCF margin is 12.5%.
How does LIVN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -17.5% (avg: 12%), ROE -20.2% (avg: 15%), current ratio 1.36 (avg: 2).